An increasing body of evidence supports the notion that both FABP3 and FABP4 serum concentrations can predict both all-cause [36,37,38,39,40,41,42] and CV mortality [40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58]; however, the potential role of these FABPs as predictive biomarkers for the mortality risk among subjects with T2D and chronic HF (CHF) has not been explored yet. Here, FABP4 is linked to congestive heart failure.